首页 › 血液癌症 › 犹他州 › Salt Lake City
Salt Lake City UT 血液癌症临床试验
8项针对 血液癌症的研究正在 Salt Lake City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
招募中2 期
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中观察性研究
- University of Utah, Salt Lake City
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
招募中观察性研究
- Primary Children's Hospital, Salt Lake City
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
招募中观察性研究
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of Utah, Salt Lake City
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
招募中3 期
- Primary Children's Hospital, Salt Lake City
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- Primary Children's Hospital, Salt Lake City
其他城市的 血液癌症试验
- Houston, TX46 项研究
- New York City, NY26 项研究
- Boston, MA25 项研究
- Washington, DC19 项研究
- Seattle, WA18 项研究
- Baltimore, MD18 项研究
- Los Angeles, CA17 项研究
- Durham, NC16 项研究
- Chicago, IL15 项研究
- Philadelphia, PA14 项研究
- Edison, NJ13 项研究
- Columbus, OH13 项研究
Salt Lake City的其他研究
- 非小细胞肺癌31 项研究
- 癌症（所有类型）27 项研究
- 乳腺癌27 项研究
- 结直肠癌22 项研究
- 肺癌21 项研究
- 黑色素瘤21 项研究
- 多发性骨髓瘤21 项研究
- 转移性癌症20 项研究
- 卵巢癌19 项研究
- 肥胖症18 项研究
- 急性髓系白血病17 项研究
- 心力衰竭17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。